United States HER2-negative Breast Cancer Market Research Report Forecast 2017 to 2022

November 2017 | 111 pages | ID: U3F73FF276AEN
S&P Consulting

Abstracts

Delivery of the Report will take 2-3 working days once order is placed.

The United States HER2-negative Breast Cancer Market Research Report Forecast 2017-2022 is a valuable source of insightful data for business strategists. It provides the HER2-negative Breast Cancer industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This HER2-negative Breast Cancer market study provides comprehensive data which enhances the understanding, scope and application of this report.

This report provides comprehensive analysis of

• Key market segments and sub-segments
• Evolving market trends and dynamics
• Changing supply and demand scenarios
• Quantifying market opportunities through market sizing and market forecasting
• Tracking current trends/opportunities/challenges
• Competitive insights
• Opportunity mapping in terms of technological breakthroughs

The Major players reported in the market include:
F. Hoffmann-La Roche
Novartis
Pfizer
AbbVie
AstraZeneca
BioMarin
Bristol-Myers Squibb
Eisai
Eli Lilly

United States HER2-negative Breast Cancer Market: Product Segment Analysis
Type 1
Type 2
Type 3

United States HER2-negative Breast Cancer Market: Application Segment Analysis
Application 1
Application 2
Application 3

Reasons for Buying this Report

• This report provides pin-point analysis for changing competitive dynamics
• It provides a forward looking perspective on different factors driving or restraining market growth
• It provides a six-year forecast assessed on the basis of how the market is predicted to grow
• It helps in understanding the key product segments and their future
• It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
• It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Contents

CHAPTER 1 HER2-NEGATIVE BREAST CANCER MARKET OVERVIEW

1.1 Product Overview and Scope of HER2-negative Breast Cancer
1.2 HER2-negative Breast Cancer Market Segmentation by Type
  1.2.1 United States Production Market Share of HER2-negative Breast Cancer by Type in 2016
  1.2.1 Type
  1.2.2 Type
  1.2.3 Type
1.3 HER2-negative Breast Cancer Market Segmentation by Application
  1.3.1 HER2-negative Breast Cancer Consumption Market Share by Application in 2016
  1.3.2 Application
  1.3.3 Application
  1.3.4 Application
1.4 United States Market Size Sales (Value) and Revenue (Volume) of HER2-negative Breast Cancer (2011-2021)

CHAPTER 2 UNITED STATES ECONOMIC IMPACT ON HER2-NEGATIVE BREAST CANCER INDUSTRY

2.1 United States Macroeconomic Analysis
2.2 United States Macroeconomic Environment Development Trend

CHAPTER 3 UNITED STATES HER2-NEGATIVE BREAST CANCER MARKET COMPETITION BY MANUFACTURERS

3.1 United States HER2-negative Breast Cancer Production and Share by Manufacturers (2015 and 2016)
3.2 United States HER2-negative Breast Cancer Revenue and Share by Manufacturers (2015 and 2016)
3.3 United States HER2-negative Breast Cancer Average Price by Manufacturers (2015 and 2016)
3.4 Manufacturers HER2-negative Breast Cancer Manufacturing Base Distribution, Production Area and Product Type
3.5 HER2-negative Breast Cancer Market Competitive Situation and Trends
  3.5.1 HER2-negative Breast Cancer Market Concentration Rate
  3.5.2 HER2-negative Breast Cancer Market Share of Top 3 and Top 5 Manufacturers
  3.5.3 Mergers & Acquisitions, Expansion

CHAPTER 4 UNITED STATES HER2-NEGATIVE BREAST CANCER PRODUCTION, REVENUE (VALUE), PRICE TREND BY TYPE

4.1 United States HER2-negative Breast Cancer Production and Market Share by Type (2012-2017)
4.2 United States HER2-negative Breast Cancer Revenue and Market Share by Type (2012-2017)
4.3 United States HER2-negative Breast Cancer Price by Type (2012-2017)
4.4 United States HER2-negative Breast Cancer Production Growth by Type (2012-2017)

CHAPTER 5 UNITED STATES HER2-NEGATIVE BREAST CANCER MARKET ANALYSIS BY APPLICATION

5.1 United States HER2-negative Breast Cancer Consumption and Market Share by Application (2012-2017)
5.2 United States HER2-negative Breast Cancer Consumption Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities
  5.3.1 Potential Applications
  5.3.2 Emerging Markets/Countries

CHAPTER 6 UNITED STATES HER2-NEGATIVE BREAST CANCER MANUFACTURERS ANALYSIS

6.1 F. Hoffmann-La Roche
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Product Type, Application and Specification
  6.1.3 Production, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Business Overview
6.2 Novartis
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Product Type, Application and Specification
  6.2.3 Production, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Business Overview
6.3 Pfizer
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Product Type, Application and Specification
  6.3.3 Production, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Business Overview
6.4 AbbVie
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Product Type, Application and Specification
  6.4.3 Production, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Business Overview
6.5 AstraZeneca
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Product Type, Application and Specification
  6.5.3 Production, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Business Overview
6.6 BioMarin
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Product Type, Application and Specification
  6.6.3 Production, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Business Overview
6.7 Bristol-Myers Squibb
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Product Type, Application and Specification
  6.7.3 Production, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Business Overview
6.8 Eisai
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Product Type, Application and Specification
  6.6.3 Production, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Business Overview
6.9 Eli Lilly
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Product Type, Application and Specification
  6.9.3 Production, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Business Overview

CHAPTER 7 HER2-NEGATIVE BREAST CANCER MANUFACTURING COST ANALYSIS

7.1 HER2-negative Breast Cancer Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of HER2-negative Breast Cancer

CHAPTER 8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 HER2-negative Breast Cancer Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of HER2-negative Breast Cancer Major Manufacturers in 2016
8.4 Downstream Buyers

CHAPTER 9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

CHAPTER 10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

CHAPTER 11 UNITED STATES HER2-NEGATIVE BREAST CANCER MARKET FORECAST (2017-2022)

11.1 United States HER2-negative Breast Cancer Production, Revenue Forecast (2017-2022)
11.2 United States HER2-negative Breast Cancer Production, Consumption Forecast by Regions (2017-2022)
11.3 United States HER2-negative Breast Cancer Production Forecast by Type (2017-2022)
11.4 United States HER2-negative Breast Cancer Consumption Forecast by Application (2017-2022)
11.5 HER2-negative Breast Cancer Price Forecast (2017-2022)

CHAPTER 12 APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of HER2-negative Breast Cancer
Table Classification of HER2-negative Breast Cancer
Figure United States Sales Market Share of HER2-negative Breast Cancer by Type in 2016
Table Application of HER2-negative Breast Cancer
Figure United States Sales Market Share of HER2-negative Breast Cancer by Application in 2016
Figure United States HER2-negative Breast Cancer Sales and Growth Rate (2011-2021)
Figure United States HER2-negative Breast Cancer Revenue and Growth Rate (2011-2021)
Table United States HER2-negative Breast Cancer Sales of Key Manufacturers (2015 and 2016)
Table United States HER2-negative Breast Cancer Sales Share by Manufacturers (2015 and 2016)
Figure 2015 HER2-negative Breast Cancer Sales Share by Manufacturers
Figure 2016 HER2-negative Breast Cancer Sales Share by Manufacturers
Table United States HER2-negative Breast Cancer Revenue by Manufacturers (2015 and 2016)
Table United States HER2-negative Breast Cancer Revenue Share by Manufacturers (2015 and 2016)
Table 2015 United States HER2-negative Breast Cancer Revenue Share by Manufacturers
Table 2016 United States HER2-negative Breast Cancer Revenue Share by Manufacturers
Table United States Market HER2-negative Breast Cancer Average Price of Key Manufacturers (2015 and 2016)
Figure United States Market HER2-negative Breast Cancer Average Price of Key Manufacturers in 2015
Figure HER2-negative Breast Cancer Market Share of Top 3 Manufacturers
Figure HER2-negative Breast Cancer Market Share of Top 5 Manufacturers
Table United States HER2-negative Breast Cancer Sales by Type (2012-2017)
Table United States HER2-negative Breast Cancer Sales Share by Type (2012-2017)
Figure United States HER2-negative Breast Cancer Sales Market Share by Type in 2015
Table United States HER2-negative Breast Cancer Revenue and Market Share by Type (2012-2017)
Table United States HER2-negative Breast Cancer Revenue Share by Type (2012-2017)
Figure Revenue Market Share of HER2-negative Breast Cancer by Type (2012-2017)
Table United States HER2-negative Breast Cancer Price by Type (2012-2017)
Figure United States HER2-negative Breast Cancer Sales Growth Rate by Type (2012-2017)
Table United States HER2-negative Breast Cancer Sales by Application (2012-2017)
Table United States HER2-negative Breast Cancer Sales Market Share by Application (2012-2017)
Figure United States HER2-negative Breast Cancer Sales Market Share by Application in 2016
Table United States HER2-negative Breast Cancer Sales Growth Rate by Application (2012-2017)
Figure United States HER2-negative Breast Cancer Sales Growth Rate by Application (2012-2017)
Table F. Hoffmann-La Roche Basic Information, Manufacturing Base, Production Area and Its Competitors
Table F. Hoffmann-La Roche HER2-negative Breast Cancer Production, Revenue, Price and Gross Margin (2012-2017)
Table F. Hoffmann-La Roche HER2-negative Breast Cancer Market Share (2012-2017)
Table Novartis Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Novartis HER2-negative Breast Cancer Production, Revenue, Price and Gross Margin (2012-2017)
Table Novartis HER2-negative Breast Cancer Market Share (2012-2017)
Table Pfizer Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Pfizer HER2-negative Breast Cancer Production, Revenue, Price and Gross Margin (2012-2017)
Table Pfizer HER2-negative Breast Cancer Market Share (2012-2017)
Table AbbVie Basic Information, Manufacturing Base, Production Area and Its Competitors
Table AbbVie HER2-negative Breast Cancer Production, Revenue, Price and Gross Margin (2012-2017)
Table AbbVie HER2-negative Breast Cancer Market Share (2012-2017)
Table AstraZeneca Basic Information, Manufacturing Base, Production Area and Its Competitors
Table AstraZeneca HER2-negative Breast Cancer Production, Revenue, Price and Gross Margin (2012-2017)
Table AstraZeneca HER2-negative Breast Cancer Market Share (2012-2017)
Table BioMarin Basic Information, Manufacturing Base, Production Area and Its Competitors
Table BioMarin HER2-negative Breast Cancer Production, Revenue, Price and Gross Margin (2012-2017)
Table BioMarin HER2-negative Breast Cancer Market Share (2012-2017)
Table Bristol-Myers Squibb Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Bristol-Myers Squibb HER2-negative Breast Cancer Production, Revenue, Price and Gross Margin (2012-2017)
Table Bristol-Myers Squibb HER2-negative Breast Cancer Market Share (2012-2017)
Table Eisai Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Eisai HER2-negative Breast Cancer Production, Revenue, Price and Gross Margin (2012-2017)
Table Eisai HER2-negative Breast Cancer Market Share (2012-2017)
Table Eli Lilly Basic Information, Manufacturing Base, Production Area and Its Competitors
Table Eli Lilly HER2-negative Breast Cancer Production, Revenue, Price and Gross Margin (2012-2017)
Table Eli Lilly HER2-negative Breast Cancer Market Share (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of HER2-negative Breast Cancer
Figure Manufacturing Process Analysis of HER2-negative Breast Cancer
Figure HER2-negative Breast Cancer Industrial Chain Analysis
Table Raw Materials Sources of HER2-negative Breast Cancer Major Manufacturers in 2016
Table Major Buyers of HER2-negative Breast Cancer
Table Distributors/Traders List
Figure United States HER2-negative Breast Cancer Production and Growth Rate Forecast (2017-2022)
Figure United States HER2-negative Breast Cancer Revenue and Growth Rate Forecast (2017-2022)
Table United States HER2-negative Breast Cancer Production Forecast by Type (2017-2022)
Table United States HER2-negative Breast Cancer Consumption Forecast by Application (2017-2022)

COMPANIES MENTIONED

F. Hoffmann-La Roche
Novartis
Pfizer
AbbVie
AstraZeneca
BioMarin
Bristol-Myers Squibb
Eisai
Eli Lilly
Galena Biopharma
Incyte
Merck
Merck Serono
Merrimack
Nektar
Tesaro